What is HC Wainwright’s Forecast for MeiraGTx Q1 Earnings?

MeiraGTx Holdings PLC (NASDAQ:MGTX) – Stock analysts at HC Wainwright reduced their Q1 2026 EPS estimates for MeiraGTx in a research note issued on Monday, April 20th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.64) for the quarter, down from their previous forecast of ($0.61). The consensus estimate for MeiraGTx’s current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for MeiraGTx’s Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.37) EPS, Q4 2027 earnings at $2.08 EPS and FY2027 earnings at $0.32 EPS.

MGTX has been the topic of several other research reports. Piper Sandler reduced their price objective on shares of MeiraGTx from $30.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, March 27th. Chardan Capital reiterated a “buy” rating and set a $35.00 price objective on shares of MeiraGTx in a research report on Friday, March 27th. Royal Bank Of Canada boosted their price target on shares of MeiraGTx from $16.00 to $24.00 and gave the stock an “outperform” rating in a research report on Friday, April 17th. Zacks Research upgraded shares of MeiraGTx from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Finally, Wall Street Zen upgraded shares of MeiraGTx from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

MeiraGTx Price Performance

MeiraGTx stock opened at $10.17 on Wednesday. The stock has a market cap of $828.35 million, a P/E ratio of -7.16 and a beta of 1.27. MeiraGTx has a 1 year low of $4.55 and a 1 year high of $11.85. The firm’s 50 day moving average price is $8.22 and its 200-day moving average price is $8.14.

MeiraGTx (NASDAQ:MGTX) last released its quarterly earnings data on Thursday, March 26th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.79. The firm had revenue of $75.36 million for the quarter, compared to analysts’ expectations of $3.87 million. MeiraGTx had a negative net margin of 140.31% and a negative return on equity of 1,065.47%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MGTX. BNP Paribas Financial Markets boosted its stake in MeiraGTx by 43.8% during the second quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock worth $31,000 after buying an additional 1,466 shares during the period. State of Alaska Department of Revenue purchased a new position in MeiraGTx during the third quarter worth $33,000. Tower Research Capital LLC TRC boosted its stake in MeiraGTx by 390.9% during the second quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock worth $57,000 after buying an additional 7,005 shares during the period. ProShare Advisors LLC purchased a new position in MeiraGTx during the fourth quarter worth $94,000. Finally, Abel Hall LLC purchased a new position in MeiraGTx during the fourth quarter worth $98,000. 67.48% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other MeiraGTx news, insider Stuart Naylor sold 27,661 shares of MeiraGTx stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $9.36, for a total transaction of $258,906.96. Following the completion of the transaction, the insider directly owned 668,505 shares of the company’s stock, valued at $6,257,206.80. The trade was a 3.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Richard Giroux sold 56,000 shares of MeiraGTx stock in a transaction on Tuesday, April 21st. The stock was sold at an average price of $10.22, for a total transaction of $572,320.00. Following the transaction, the chief financial officer directly owned 971,530 shares of the company’s stock, valued at $9,929,036.60. The trade was a 5.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 145,661 shares of company stock valued at $1,290,647 over the last three months. 7.50% of the stock is owned by company insiders.

MeiraGTx News Summary

Here are the key news stories impacting MeiraGTx this week:

• Positive Sentiment: HC Wainwright revised several multi?quarter and full?year forecasts, raising Q3 and Q4 2026 EPS views and nudging FY2026 less negative (from ($2.43) to ($2.37)). The firm also issued a positive FY2027 outlook (EPS $0.32) and a Q4 2027 estimate of $2.08 — signaling a path toward profitability that can support higher valuation expectations. Read More.
• Positive Sentiment: Shares jumped on above?average volume in the latest session (Zacks flagged a ~6.8% surge), which can attract momentum buyers and short?term traders following the analyst revisions and recent strong quarter. Read More.
• Neutral Sentiment: CFO Richard Giroux sold 56,000 shares at an average $10.22 under a pre?arranged Rule 10b5?1 plan; he still holds a large stake. Because the sale was planned and disclosed, it’s less a governance red flag but may still be viewed by some as profit?taking. Read More.
• Neutral Sentiment: Institutional ownership is meaningful (~67.5%) and a mix of recent incremental buys by several funds was reported — that can stabilize trading but also concentrate risk among large holders. Read More.
• Negative Sentiment: HC Wainwright trimmed near?term 2026 quarter estimates for Q1 and Q2 (small downgrades to Q1: ($0.61) ? ($0.64); Q2: ($0.59) ? ($0.60)), indicating continued near?term losses and operational headwinds that could pressure sentiment if guidance or cash?flow visibility doesn’t improve. Read More.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.